Rethinking Clinical Trials

FEBRUARY 12, 2025

In this Friday’s PCT Grand Rounds, Angelo Volandes of Dartmouth Health and James Tulsky of Dana-Farber Cancer Institute will present “A Cluster Randomized, Stepped-Wedge Pragmatic Trial to Enhance Goals-of-Care Communication for Older Adults With Cancer (ACP-PEACE).” The Grand Rounds session will be held on Friday, February 14, 2025, at 1:00 pm eastern.

Trials 146

Trials Medicine Clinical Trials Clinical Trials 146

Pharmaceutical Technology

FEBRUARY 12, 2025

Merck acquisition target SpringWorks will go toe-to-toe with AstraZeneca in the US neurofibromatosis market.

FDA Approval 264

FDA Approval Drugs Marketing 264

Bio Pharma Dive

FEBRUARY 12, 2025

A small semaglutide trial suggests the medicine's suppression of appetite may extend to alcohol, but larger tests are needed to establish a conclusive benefit.

Medicine 199

Medicine Trials Drugs 199

Pharmaceutical Technology

FEBRUARY 12, 2025

GlobalDatas Revati Tatake discussed key trends in biopharma which are set to have an impact in 2025 and beyond.

Clinical Trials 162

Clinical Trials Clinical Trials Trials 162

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

Medicine

Bio Pharma Dive

FEBRUARY 12, 2025

Proceeds will support testing of drugs designed to suppress hunger in people with the tough-to-treat rare disease and, potentially, more common obesity-related conditions.

Drugs 167

Drugs 167

Pharmaceutical Technology

FEBRUARY 12, 2025

Traveres stock price climbed by 14% following the announcement it will seek an FDA label expansion for Filspari.

Trials 162

Trials Drugs 162

Pharmaceutical Technology

FEBRUARY 12, 2025

The funding will be used to complete the Phase II/III trial of ulviprubart, and to support commercial launch preparation.

Drugs 147

Drugs Trials 147

Bio Pharma Dive

FEBRUARY 12, 2025

The agreement hands Biogen as much as $250 million in exchange for milestone payments and sales royalties for litifilimab, which is in a pair of late-stage studies in lupus.

Sales 135

Sales Drugs 135

Pharmaceutical Technology

FEBRUARY 12, 2025

Lundbeck has received the US FDA fast track designation for amlenetug, a potential treatment for multiple system atrophy (MSA).

147

147

ACRP blog

FEBRUARY 12, 2025

Many times, individuals who have triumphed over frightening, or even near-death, situations will say that the experience has given them a new and more positive outlook on life. Allison Massari, a two-time survivor of such scenarios, has an additional and unique insightand its on the patient experience. She celebrates how healthcare professionals have an exceptional power to transform lives, and will share her perspective on how compassionate care can be incorporated into clinical research in a S

Clinical Research 59

Clinical Research Research Clinical Trials Clinical Trials 59

Advertisement

Clinical Supply

Pharmaceutical Technology

FEBRUARY 12, 2025

EC has granted marketing authorisation to BridgeBio Pharmas acoramidis under the Beyonttra brand name for treating ATTR-CM.

Marketing 147

Marketing Branding 147

AuroBlog - Aurous Healthcare Clinical Trials blog

FEBRUARY 12, 2025

(Dusty Pixel photography/Getty Images) An emerging strain of highly pathogenic avian influenza has spilled over from wild birds to dairy cows in the state of Nevada, and officials at the US Department of Agriculture (USDA) and some scientists are concerned by a mutation they are seeing. The viral variant, called genotype D1.

Genotype 130

Genotype Scientist Clinical Trials Clinical Trials 130

Pharmaceutical Technology

FEBRUARY 12, 2025

Health Canada has approved MSD's Keytruda for treating adults with resectable stage II, IIIA or IIIB NSCLC.

147

147

Bio Pharma Dive

FEBRUARY 12, 2025

District Judge John Bates wrote the removals harm “everyday Americans, and most acutely, underprivileged Americans, seeking healthcare.

130

130

Advertisement

White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations

Clinical Trials

Pharma Times

FEBRUARY 12, 2025

UCB's BIMZELX reveals promising two-year data at EHSF 2025

114

114

AuroBlog - Aurous Healthcare Clinical Trials blog

FEBRUARY 12, 2025

The proposed budget allocation for the Central sector schemes of Department of Health Research (DHR), under the ministry of health and family welfare, is expected see an increase of almost 40 per cent during the fiscal year 2025-26, as compared to the initial projects under the Budget Estimates (BE) for the fiscal year 2024-25.

Research 113

Research Clinical Trials Clinical Trials Trials 113

pharmaphorum

FEBRUARY 12, 2025

Merck KGaA is talking to SpringWorks about a takeover, and FDA approval for a neurofibromatosis drug could have sweetened any potential deal.

FDA Approval 96

FDA Approval Drugs 96

Pharma Times

FEBRUARY 12, 2025

Potential treatment for multiple system atrophy shows promise

87

87

Advertisement

Clinical Supply

pharmaphorum

FEBRUARY 12, 2025

Abcuro has raised $200m in financing that should allow it to complete a pivotal trial of ulviprubart for rare disease inclusion body myositis (IBM).

Marketing 89

Marketing Drugs Trials 89

Pharmaceutical Commerce

FEBRUARY 12, 2025

The facilities are expected to offer pharma shipment support by addressing time and temperature-specific requirements.

59

59

pharmaphorum

FEBRUARY 12, 2025

BridgeBio and Bayer are poised to challenge Pfizer's Vyndaqel in the EU after acoramidis gets a green light for ATTR cardiomyopathy.

Drugs 78

Drugs 78

Pharmaceutical Commerce

FEBRUARY 12, 2025

In the third part of her video interview with Pharma Commerce Editor Nicholas Saraceno, Jenna Dale, director of client relations at Cencora, dives into specific areas where FDA investment could have the greatest impact in accelerating approval timelines.

Development 59

Development 59

Advertisement

This new white paper defines and details the impact of Decentralized Clinical Trials on the Pharmaceutical industry and how the impact can be measured along with steps companies can take to ensure adoption.

Clinical Trials

pharmaphorum

FEBRUARY 12, 2025

An e-Book aimed at children with rare kidney disease aHUS can help them understand the condition, deal with emotions, and find support, says Alexion.

66

66

Pharmaceutical Commerce

FEBRUARY 12, 2025

Digging a little deeper into the drug class phenomenon reveals some interesting takeaways on a smaller subgroup of users.

Drugs 52

Drugs 52

pharmaphorum

FEBRUARY 12, 2025

Learn how pharmaceutical companies can accelerate construction projects in the biotech and manufacturing sectors by implementing innovative strategies and best practices.

Manufacturing 59

Manufacturing 59

Pharmaceutical Commerce

FEBRUARY 12, 2025

Our February issue is highlighted by an examination of the latest trends and strategies from the perspective of third-party logistics providers, and introduces new expert commentary covering a pair of pivotal realms in the pharma supply chain journey.

52

52

Advertisement

Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud

Clinical Research

pharmaphorum

FEBRUARY 12, 2025

Join us in our exclusive interview with JP Morgan covering the highlights of Week 2025 and insights from Paul Hastings. Watch the video to get valuable information and updates.

52

52

Pharmaceutical Commerce

FEBRUARY 12, 2025

Click the title above for a link to open the Pharmaceutical Commerce February 2025 issue in an interactive PDF format.

52

52

XTalks

FEBRUARY 12, 2025

Boehringer Ingelheim has announced a major breakthrough following positive topline data from its Phase III FIBRONEER-ILD trial on progressive pulmonary fibrosis (PPF). The study met its primary endpoint by demonstrating a significant absolute change in forced vital capacity (FVC) at Week 52 compared to placebo. FVC, which measures the total amount of air exhaled during a forceful breath, serves as a key indicator of lung health.

Clinical Trials 66

Clinical Trials Clinical Trials Trials FDA Approval 66

Pharmaceutical Commerce

FEBRUARY 12, 2025

The latest news for pharma industry insiders.

52

52

Advertisement

Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.

Clinical Trials